Itaconic acid (ITA) is a byproduct of the tricarboxylic acid (TCA) cycle, produced when the enzyme aconitate decarboxylase 1 (ACOD1/IRG1) converts the TCA intermediate cis-aconitate. For a long time it sat in biochemistry textbooks without much fanfare. That’s changed. Over the past decade, researchers have established that ITA is not just metabolic waste — it actively shapes macrophage behavior, dampens inflammatory signaling, and shows measurable protective effects in animal models of autoimmune disease, liver injury, lung pathology, cancer, and both bacterial and viral infection.
This review covers the core mechanisms through which ITA and its synthetic derivatives (dimethyl itaconate/DI and 4-octyl itaconate/4-OI) regulate immune inflammation, followed by a disease-by-disease breakdown of where the research currently stands.
What is itaconic acid, and why does it matter?
Itaconic acid is an unsaturated dicarboxylic acid. It’s produced in macrophages and certain other immune cells during inflammatory activation, particularly after lipopolysaccharide (LPS) stimulation. A landmark paper in Nature reported that LPS-activated macrophages dramatically upregulate ITA production, and that ITA functions not just as a metabolic marker but as an active anti-inflammatory regulator.
Because ITA itself has limited cell permeability, researchers developed two cell-permeable derivatives for experimental use: dimethyl itaconate (DI) and 4-octyl itaconate (4-OI). Both mimic the biological activity of endogenous ITA and have become standard tools for studying the molecule’s effects in vitro and in vivo.
How itaconic acid regulates immune inflammation
1. Glycolysis inhibition
When macrophages shift from oxidative phosphorylation to aerobic glycolysis during inflammation, that metabolic switch amplifies the inflammatory response. ITA interferes with this process at several points.
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) controls the rate of aerobic glycolysis. 4-OI alkylates GAPDH at its Cys22 site, reducing enzyme activity and slowing glycolysis — which in turn reduces macrophage activation and IL-1β release. Overexpressing wild-type GAPDH reverses this effect; overexpressing the Cys22 mutant does not, confirming the alkylation site as the functional target.
ITA also impairs glycolytic flux by targeting fructose bisphosphate aldolase A (ALDOA), as shown by proteomic profiling.
In a cancer context, 4-OI suppresses lactate production and GAPDH activity to promote cuproptosis in colorectal cancer cells — a separate mechanism, but still rooted in glycolytic interference.
2. Nrf2 activation and antioxidant signaling
Nrf2 is a transcription factor that regulates cellular oxidative stress responses. Under resting conditions, KEAP1 tags Nrf2 for degradation. Electrophilic compounds like ITA and its derivatives separate the KEAP1-Nrf2 complex, allowing Nrf2 to move into the nucleus and turn on downstream antioxidant genes including SOD, GPX4, xCT, and HO-1.
This pathway is important across multiple disease contexts. ITA-mediated Nrf2 activation has been documented in models of pulmonary fibrosis, acute kidney injury, liver damage, and ischemia-reperfusion injury.
3. NLRP3 inflammasome suppression
The NLRP3 inflammasome is one of the more studied inflammatory signaling complexes, and its activation is a hallmark of several inflammatory conditions. ITA suppresses NLRP3 by more than one route.
ITA inhibits NLRP3 expression directly. It also blocks Caspase-1 activation and reduces GSDMD cleavage — the protein responsible for the pore-forming cell death called pyroptosis. The Cys77 site on GSDMD appears to be a likely alkylation target for ITA, though this is still being characterized.
4-OI also blocks NLRP3 activation in allergic airway inflammation by suppressing oxidative stress and mitochondrial fusion/fission dynamics.
A separate study using volume-regulated anion channels (VRAC) found that these channels modulate ITA efflux, which in turn influences NLRP3 activation — suggesting the regulation is bidirectional and more complex than a simple on/off switch.
4. ATF3/IκBζ axis modulation
ATF3 is a stress-induced transcription factor with anti-inflammatory properties. It represses IκBζ, a nuclear protein that drives IL-6 production. ITA and DI upregulate ATF3, thereby suppressing IκBζ-dependent inflammatory gene expression.
Importantly, this effect is partially independent of Nrf2 — knocking out Nrf2 doesn’t fully abolish ITA’s ability to suppress IκBζ, but knocking out ATF3 significantly weakens it.
5. Type I interferon regulation
Type I IFNs (particularly IFN-β) are central to antiviral responses, but they also drive pathology in some autoimmune conditions. ITA has divergent effects depending on context.
Endogenous ITA appears to promote IFN-β secretion in LPS-stimulated macrophages. By contrast, DI and 4-OI suppress LPS-induced IFN-β. In IRG1-knockout macrophages, type I IFN downstream gene expression is visibly impaired, and restoring ITA rescues this signaling — suggesting ITA supports baseline type I IFN function while derivatives can suppress it in pro-inflammatory settings.
4-OI also activates Nrf2 to broadly repress type I IFN responses, and has been found to suppress Tissue Factor (F3) expression in macrophages, potentially functioning as an anticoagulant in inflammatory states.
6. cGAS-STING pathway inhibition
The cGAS-STING axis is the main cytosolic double-stranded DNA sensing pathway, feeding into TBK1 and IRF3 to produce type I IFNs and inflammatory cytokines. 4-OI does not affect cGAS, TBK1, or IRF3 directly. Instead, it blocks STING activation by preventing its palmitoylation at the Cys91 site and inhibiting STING oligomerization.
A related study found that 4-OI alkylates STING at Cys147, blocking phosphorylation and downstream cytokine production — and this occurs in an Nrf2-independent manner.
7. Additional mechanisms
ITA also inhibits TET DNA dioxygenases (particularly TET2), enzymes that regulate DNA demethylation and thus epigenetic gene expression. This links ITA to epigenetic anti-inflammatory control.
The ATP-binding cassette transporter ABCG2 exports ITA from macrophages, limiting innate immune responses and dampening TFEB-dependent lysosomal activity — which has implications for antibacterial immunity.
Disease research: where itaconic acid fits
Cancer
ITA’s relationship with cancer is not straightforward. In colorectal cancer, 4-OI promotes cuproptosis and ferroptosis, enhancing sensitivity to chemotherapy (oxaliplatin, lobaplatin). DI selectively targets inflammatory and metabolic vulnerabilities in chronic lymphocytic leukemia (CLL).
On the flip side, in hepatocellular carcinoma (HCC), IRG1-knockout mice show significantly suppressed tumor growth, suggesting IRG1 can act as an oncogene in certain contexts. The mechanism involves itaconate-mediated promotion of CD8+ T cell exhaustion through epigenetic mechanisms — essentially the tumor co-opting ITA production to suppress anti-tumor immunity.
This dual role (anti-inflammatory in some settings, immunosuppressive in others) is one of the more uncomfortable findings in the ITA literature, and it matters for anyone thinking about therapeutic applications.
Autoimmune diseases
ITA and its derivatives reduce Th17/Treg imbalance, a core driver of autoimmune pathology. ASO-mediated reduction of ITA promotes Treg differentiation and reduces Th17 cells in autoimmune models.
In autoimmune prostatitis, 4-OI activates Nrf2/HO-1 to block NLRP3-mediated pyroptosis. In systemic lupus erythematosus (SLE), 4-OI treatment lowered anti-RNP autoantibodies, immune cell activation markers, and type I IFN levels, while increasing Treg populations — with a reasonably coherent mechanistic story.
4-OI also reduced collagen synthesis and TGF-β1-driven fibroblast activation in systemic sclerosis, in a Nrf2-dependent way. In autoimmune hepatitis induced by Concanavalin A, 4-OI reduced liver histopathology, serum ALT/AST, macrophage infiltration, and pro-inflammatory cytokines.
Lung disease
IRG1 is highly expressed in the lungs during acute lung injury, and the ITA it produces activates Nrf2 and promotes autophagy to reduce inflammation. 4-OI reduces bleomycin-induced pulmonary fibrosis by both directly blocking epithelial-mesenchymal transition and reducing macrophage M1 polarization.
In an allergic asthma model, intranasal 4-OI attenuated airway hyperresponsiveness and Th2 immune responses — the IRG1/itaconate pathway is now considered a potential therapeutic target for allergic asthma.
Liver disease
4-OI has shown benefit in multiple liver injury models. In acute liver injury (CCl4-induced), it reduces pro-inflammatory cytokine secretion and macrophage/neutrophil infiltration, partly through suppressing NF-κB nuclear translocation.
In liver fibrosis, IRG1 expression rises in fibrotic liver, and supplementing 4-OI in IRG1-knockout mice activates Nrf2 and inhibits TGF-β1/Smad signaling. In ischemia-reperfusion injury, ITA protection may involve lncRNA-mediated mechanisms.
4-OI also shows potential in non-alcoholic fatty liver disease by reducing AKT inhibition and oxidative stress.
A particularly interesting study used artificial cells loaded with ITA to induce “memory-like” anti-inflammatory macrophages — capable of specifically reversing acute liver failure (ALF) and preventing reinjury. That’s the kind of applied translation that moves a molecule from interesting to clinically relevant.
Kidney disease
4-OI attenuates LPS-induced acute kidney injury by activating Nrf2, inhibiting STAT3 signaling, and reducing NLRP3 and IL-1β expression. It also improves mitochondrial autophagy.
The IRG1-itaconate axis protects kidney cells from oxidative stress and prevents macrophage activation. In renal fibrosis, 4-OI inhibits TGF-β/Smad and NF-κB signaling, reduces ROS, and suppresses autophagy-related fibrosis.
Bacterial and viral infection
4-OI directly inhibits influenza A replication by targeting the nuclear export protein CRM1, blocking viral ribonucleoprotein complex export from the nucleus.
4-OI and DMF suppress SARS-CoV-2 replication by inducing antiviral programs and blocking the COVID-19-associated inflammatory response. Their anticoagulant activity (suppressing Tissue Factor via type I IFN inhibition) may also be relevant to COVID-19 coagulopathy.
During Staphylococcus aureus pneumonia, IRG1 is selectively expressed in neutrophils, producing ITA that suppresses glycolysis and oxidative burst — which reduces excess inflammation but also impairs bacterial clearance. That’s the tradeoff.
The picture that’s forming
ITA sits at the intersection of cellular metabolism, oxidative stress response, and immune signaling. It’s produced by activated macrophages as part of an internal regulatory loop — the cell makes more ITA as inflammation increases, and ITA then feeds back to limit further inflammatory activation.
The multiple mechanisms (GAPDH alkylation, Nrf2 activation, NLRP3 suppression, ATF3 upregulation, cGAS-STING inhibition, TET2 inhibition) suggest ITA targets several distinct pathways simultaneously. Whether this multi-target profile is an asset or a liability for drug development depends heavily on the disease context.
The HCC finding — where ITA promotes tumor progression rather than suppressing it — is a meaningful complication. Any therapeutic strategy built around ITA enhancement needs to account for the possibility of unintended immunosuppression in oncology settings.
Still, for inflammatory and autoimmune diseases, the preclinical data is substantial. The cell-permeable derivatives (4-OI in particular) have demonstrated efficacy across enough models that clinical exploration seems justified.
FAQ
Q: What is itaconic acid, and where does it come from in the body?
Itaconic acid is an organic unsaturated dicarboxylic acid produced in the body when the enzyme ACOD1 (also known as IRG1) converts cis-aconitate — an intermediate in the TCA cycle — during immune activation. Macrophages are the primary source, particularly after stimulation by LPS or other inflammatory signals.
Q: What is the difference between itaconic acid and its derivatives like 4-OI and DI?
Natural itaconic acid has poor cell membrane permeability, which limits its use in cell-based experiments. 4-octyl itaconate (4-OI) and dimethyl itaconate (DI) are synthetic derivatives designed to cross cell membranes more efficiently. They share the core biological activities of itaconic acid — anti-inflammatory, antioxidant, and immune-modulatory — but they are not identical in all effects. For example, 4-OI and DI can suppress IFN-β secretion, while endogenous ITA appears to promote it in some contexts.
Q: How does itaconic acid suppress inflammation?
ITA uses several distinct routes. It alkylates GAPDH at the Cys22 site to slow glycolysis and reduce macrophage activation. It activates the Nrf2 transcription factor to upregulate antioxidant enzymes. It suppresses the NLRP3 inflammasome, partly by alkylating GSDMD to block pyroptosis. It upregulates ATF3, which in turn represses IκBζ and IL-6 production. It also blocks STING palmitoylation and oligomerization, dampening the cGAS-STING inflammatory signaling pathway.
Q: Does itaconic acid always reduce inflammation, or can it have opposite effects?
Mostly anti-inflammatory, but not always. In hepatocellular carcinoma (HCC), itaconate promotes CD8+ T cell exhaustion through epigenetic mechanisms, effectively suppressing anti-tumor immunity and supporting tumor progression. IRG1-knockout mice showed significantly reduced HCC growth in one study. So in cancer contexts — particularly liver cancer — elevated itaconate can be counterproductive. This is a recognized complication in the field.
Q: What diseases have been studied in animal models?
Preclinical research has covered autoimmune diseases (SLE, autoimmune hepatitis, systemic sclerosis, autoimmune prostatitis), liver diseases (acute injury, fibrosis, ischemia-reperfusion, non-alcoholic fatty liver), lung diseases (acute lung injury, pulmonary fibrosis, allergic asthma), kidney diseases (acute kidney injury, renal fibrosis), cancer (colorectal cancer, CLL, HCC), and infections (influenza A, SARS-CoV-2, Staphylococcus aureus).
Q: Is itaconic acid being developed as a drug?
Not yet in clinical use. Current research is primarily preclinical (cell and animal models). The derivatives 4-OI and DI are research tools rather than approved therapeutics. The breadth of preclinical evidence is substantial enough that clinical investigation would be justified for specific indications, but regulatory-grade development has not been publicly reported as of the time of this review.
Q: How does itaconic acid affect macrophage function specifically?
Itaconic acid is central to macrophage metabolic reprogramming during inflammation. LPS-activated macrophages upregulate IRG1 and produce large amounts of ITA, which then feeds back to reduce further activation — a form of internal regulation. ITA shifts macrophages away from glycolysis, reduces NLRP3-mediated pyroptosis, and can induce what researchers have called “memory-like” anti-inflammatory macrophage states. It also influences macrophage polarization: 4-OI reduces M1 macrophage polarization (pro-inflammatory) in pulmonary fibrosis models.
Q: What is the significance of ABCG2 in itaconic acid biology?
ABCG2 is a transporter protein that pumps itaconate out of macrophages. A 2024 study found that ABCG2-mediated ITA export limits innate immune responses and suppresses TFEB-dependent lysosomal biogenesis. This means ABCG2 could be a target for enhancing antibacterial immunity — by blocking ITA export, you could potentially restore the macrophage’s antimicrobial capacity. It also adds another layer of regulation to how ITA levels are controlled in immune cells.